Jörg Jabkowski Almute Loidl Barbara Auinger Helmut Kehrer Norbert Sepp Robert Pichler
10.3389/fimmu.2021.606056
Front Immunol
2021 Jun 18;12:606056.
fdg pet melanoma pembrolizumab thyroiditis
CC BY
https://pubmed.ncbi.nlm.nih.gov/34220792/
Antibodies, Monoclonal, Humanized / adverse effects B7-H1 Antigen / metabolism CD4-Positive T-Lymphocytes / immunology Drug-Related Side Effects and Adverse Reactions / diagnosis Histiocytes / immunology Immune Checkpoint Inhibitors / adverse effects Immunotherapy / methods Melanoma / drug therapy Skin Neoplasms / drug therapy Thyroid Gland / pathology Thyroiditis / diagnosis
Antibodies, Monoclonal, Humanized / adverse effects B7-H1 Antigen / metabolism CD4-Positive T-Lymphocytes / immunology Drug-Related Side Effects and Adverse Reactions / diagnosis Histiocytes / immunology Immune Checkpoint Inhibitors / adverse effects Immunotherapy / methods Melanoma / drug therapy Skin Neoplasms / drug therapy Thyroid Gland / pathology Thyroiditis / diagnosis Case Reports Antibodies, Monoclonal, Humanized / therapeutic use Cell Movement Humans Immune Checkpoint Inhibitors / therapeutic use Male Melanoma / complications Melanoma / diagnosis Middle Aged Neoplasm Metastasis Neoplasm Staging Skin Neoplasms / complications Skin Neoplasms / diagnosis Thyroid Gland / immunology Thyroidectomy Thyroiditis / etiology Antibodies, Monoclonal, Humanized B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors pembrolizumab
PMC8250423
34220792
Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report
2021